Visão geral da empresa
A clinical-stage specialty pharmaceutical enterprise, Vyome Holdings, Inc. focuses on developing therapeutic products designed to address immuno-inflammatory and rare diseases within the United States market. The company operates primarily within the Healthcare sector, specifically targeting the Biotechnology industry, which implies a high-risk, high-reward profile characterized by significant research and development expenditures before commercialization. Currently, the business is supported by a lean operational structure employing just nine individuals, reflecting its early-stage development phase. With a market capitalization of $15.37M and trailing twelve-month revenue of $319,714, the firm represents a micro-cap entity with limited market penetration relative to established pharmaceutical peers. These valuation metrics indicate that the company is trading with a premium valuation relative to its current sales volume, suggesting that the market price anticipates future commercial success from its pipeline rather than reflecting existing operational cash flows. The disparity between the small revenue base and the market cap highlights that investors are pricing in potential future value from the lead product candidate VT-1953, which targets dual DNA Gyrase inhibition, rather than current profitability.
Saúde financeira
The company reported a revenue of $319,714 over the trailing twelve months, yet it recorded a net income of $-10,262,007 and an EBITDA of $-2,735,052, revealing a cost structure where expenses vastly exceed sales, a typical characteristic of clinical-stage biotechnology firms investing heavily in R&D. Despite the reported net loss, the company maintains a free cash flow of $5.11M, which provides a critical buffer for financial flexibility by allowing the firm to fund ongoing research and development activities without immediate dilution or external financing. The gross margin stands at 68.4%, indicating that the cost of goods sold is relatively low compared to revenue, whereas the operating margin of -3707.4% and profit margin of 0.0% reflect the massive overhead costs associated with clinical trials and regulatory compliance that have not yet been offset by commercial sales. The balance sheet shows a cash position of $4.98M against total debt of $31,258, resulting in a debt-to-equity ratio of 0.83, which suggests a leveraged but manageable capital structure given the minimal absolute debt load. Liquidity is supported by a current ratio of 1.99, indicating that the company possesses nearly double the current assets required to cover its short-term liabilities, thereby reducing the risk of immediate insolvency. Furthermore, the return on equity is listed as N/A due to the lack of attributable earnings, while the return on assets stands at -43.6%, signaling that the current asset base is generating negative returns in the short term, a common metric for pre-revenue biotech firms.
Avaliação de valorização
Trailing P/E and forward P/E ratios are both listed as N/A, which implies that the earnings trajectory is currently undefined and that traditional earnings-based valuation models cannot be applied to this speculative asset. The price-to-book ratio is 5.30, indicating that the market values the company at more than five times its net asset value, a significant premium that reflects the intangible value of the intellectual property and pipeline potential rather than tangible book worth. Alternative valuation metrics such as the price-to-sales ratio of 48.08 and an EV/EBITDA of -4.29 further underscore that the stock is priced based on revenue multiples rather than profitability, suggesting investors expect substantial future revenue expansion to justify current prices. The stock has exhibited extreme volatility, with a 52-week high of $56.40 and a low of $1.75; without a specific current price provided in the source data, the range demonstrates a massive expansion from its depressed levels, potentially indicating a significant rebound or speculative surge. Although the beta is listed as N/A, preventing a direct comparison to broader market volatility, the wide swing between the high and low suggests that the asset is highly sensitive to clinical trial outcomes or regulatory news typical of the biotechnology sector. The negative EV/EBITDA combined with a high price-to-book suggests that the market is willing to pay a heavy premium for a company that currently generates negative earnings, relying entirely on the perceived success of future product candidates to realize value.
Growth & Income
Revenue growth year-over-year stands at -40.5%, while earnings growth is N/A, indicating that the company is currently shrinking in terms of sales and has no historical earnings trajectory to measure against. The decline in revenue suggests that the company may be in a transition period, potentially winding down certain segments or shifting focus toward its lead product candidate, which could result in a temporary contraction before commercialization begins. Since the company does not pay dividends, with a dividend yield of N/A and a payout ratio of 0.0%, all available capital is theoretically available for reinvestment into research and development rather than being distributed to shareholders. This reinvestment strategy is standard for clinical-stage biotechnology firms, as paying dividends would deplete the cash reserves needed for expensive clinical trials and regulatory filings. Consequently, the overall growth and income profile is characterized by negative near-term revenue performance and a complete reliance on capital appreciation driven by pipeline milestones rather than income generation or dividend support. The absence of dividend income combined with negative revenue growth highlights that the primary source of potential value creation lies entirely in the successful advancement of therapeutic products through clinical stages.